The firm's transplant allograft status test identifies genetic biomarkers that predict the likelihood of a patient's immune system to reject the organ over time.
The XW-100 Automated Hematology Analyzer previously received 510(k) clearance. With the CLIA waiver, the test can be run in more types of healthcare facilities.
The investment is part of a Series C financing round that will also include other investors. Seventh Sense is developing a new type of blood collection device to improve patient compliance.
DxTerity aims to develop a genomic blood test to identify which cancer patients are most likely to benefit from radiation therapy or are at risk for toxicity.
Alere is divesting Epocal as it seeks regulatory approval of its merger with Abbott. Based in Ottawa, Ontario, Epocal develops point-of-care blood diagnostic systems.